PR5-LL-CM01 is a novel selective, small-molecule inhibitor of PRMT5 methyltransferase with IC50 of 7.5 uM.

PQC 083 is a novel nerve growth factor (NGF) antagonist with IC50 of 7.0 uM, functionally inhibits NGF's effects on PC12 cell differentiation.

PptT inhibitor 8918 (Compound 8918) is a mycobactericidal amidino-urea compound that targets phosphopantetheinyl transferase (PptT, IC50=2.5 uM), shows an MIC90 of 3.1 uM against Mtb H37Rv.

PPTN is a potent, highly specific amtagonist of P2Y14 receptor with Ki of 0.4 nM in functional assays.

PPTN is a potent, highly specific amtagonist of P2Y14 receptor with Ki of 0.4 nM in functional assays.

PPI-2458 is potent, specific, irreversible methionine aminopeptidase-2 (MetAP-2) inhibitor with IC50 of 0.2 nM, inhibits growth inhibition of HFLS-RA and HUVEC with IC50 of 0.04 nM.

PPBI is a novel potent, selective, full M1 muscarinic agonist with EC50 of 5, 8, and 21 nM for human, rat, and mouse M1 receptors, respectively.

PPARα activator compound 3 is a specific PPAR activator that selectively up-regulates PPARα transcriptional activity, leading to PPARα target gene expression both in vitro and in vivo.

PP1 inhibitor C31 is a 1E7-03 analog and protein phosphatase 1 (PP1) targeting small molecule with Kd of 1.88 uM, inhibits Ebola virus (EBOV) transcription and replication.

Potent and selective DA uptake inhibitor

Potassium thioacetate is widely used as a sulfur source in the synthesis of sulfur-containing organic compounds. It has been employed for the synthesis of heterocycles, polymers, transition-metal ligands, nanoparticles, bioactive compounds and macromolecu

Potassium iodide

Pomaglumetad Methionil (LY2140023 monohydrate) is the methionine amide prodrug of the mGluR2/3 agonist LY-404039 with the potential oral treatment of schizophrenia..

Polydatin(Piceid)

Poloppin II is an orally active, Poloppin derivative inhibitor of protein-protein interaction via the PBD of the mitotic Polo-like kinase (PLK) with IC50 of 41 uM in FP assays, exhibits IC50 of 61 nM cellular assay for mitotic arrest.

PNRI-299 is an inhibitor of activator protein-1 (AP-1) transcription (IC(50) of 20 microM) without affecting NF-kappaB transcription (up to 200 microM) or thioredoxin (up to 200 microM).

PNR-7-02 is a specific inhibitor of human DNA Polymerase η (hPol η) with IC50 of 8 uM, exhibits 5-10-fold specificity for hPol η over other replicative Pols.

PNPLA4-IN-1 is a potent, selective, and irreversible PNPLA4 inhibitor with IC50 of 1.8 uM (separated membrane proteome fraction), shows in-cell inhibition of PNPLA4 with IC50 of 11.7 uM..

PM-43I is a selective inhibitor of STAT5/6 Src Homology 2 (SH2) domain, binds recombinant STAT6 and STAT5B (IC50=1.8 and 3.8 uM) with much lower affinity for STAT3 (IC50=29.9 uM).

PLK1-IN-14f is a potent PLK1 inhibitor, exhibits potent activity against a panel cancer cell lines with GI50 values ranging from 0.30 to 0.60 uM.

PL265 (PL-265) is a dual enkephalinase inhibitor, alleviate corneal pain and inflammation in vivo..

PKC-IN-7 is a potent, selective, reversible, ATP-competitive PKCα/β inhibitor with IC50 of 4.7/3.3 nM.

PKC-IN-1 is a poent PKC beta II inhibitor with Ki of 14.9 nM, extracted from patent WO 2008096260 A1 as compound example H6..

PK-7088 is a small molecule mutant p53 Y220C reactivator, promotes correct folding of Y220 mutant p53 and induces expression of p53 targets p21 and the Noxa, triggers nuclear export of the pro-apoptotic Bax protein to mitochondria..

PK4C9 (Homocarbonyltopsentin) is a small-molecule stem-loop RNA structure TSL2-binding compound (EC50=16.1 uM) that increases SMN2 exon 7 (E7) splicing and rescues downstream molecular alterations in SMA cells.

PJ-68 is a potent, selective inhibitor of arginine methyltransferase PRMT5 with IC50 of 517 nM, shows no inhibitory activity against type I PRMT family members ( (PRMT1, 3, 4, 6, and 8).

Pizotifen malate

Pivmecillinam(Amdinocillin pivoxil) is an orally active prodrug of mecillinam, an extended-spectrum penicillin antibiotic.

Pitavastatin Calcium is a competitive inhibitor of the enzyme HMGCR (HMG-CoA reductase) results in a reduction in LDL cholesterol synthesis.

PIT-1 is a specific PIP3 antagonist that disrupts PIP3/Akt PH domain binding with IC50 of 30 uM, Kd of 43.2 uM.